| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 10/03/2023 |
3
| Mathias Sheila (Chief Scientific Officer) has filed a Form 3 on Virpax Pharmaceuticals, Inc. |
| 08/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/16/2023 |
4/A
| Shah Vinay (CFO) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.99, valued at
$99k
|
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
8-K
| Quarterly results |
| 06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/07/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 06/07/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G/A
| Mack Anthony P. reports a 26.1% stake in VIRPAX PHARMACEUTICALS, Inc. |
| 02/07/2023 |
4/A
| Mack Anthony P. (CEO) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 125,000 options to buy
@ $0.867, valued at
$108.4k
|
|
| 01/27/2023 |
4
| Gudin Jeffrey (Chief Medical Officer) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 50,000 options to buy
@ $0.788, valued at
$39.4k
|
|
| 01/27/2023 |
4
| Mack Anthony P. (CEO) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 125,000 options to buy
@ $0.788, valued at
$98.5k
|
|
| 01/27/2023 |
4
| Chipman Christopher Michael (CFO) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 112,000 options to buy
@ $0.788, valued at
$88.3k
|
|
| 01/26/2023 |
SC 13G/A
| Kepos Capital LP reports a 0% stake in Virpax Pharmaceuticals, Inc. |
| 01/10/2023 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 8.4% stake in Virpax Pharmaceuticals, Inc. |
| 01/04/2023 |
4
| Jambulingam Thani (Director) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 40,000 options to buy
@ $0.622, valued at
$24.9k
|
|
| 01/04/2023 |
4
| Floyd Eric (Director) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 45,000 options to buy
@ $0.622, valued at
$28k
|
|
| 01/04/2023 |
4
| Sendrow Jerrold (Director) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 35,000 options to buy
@ $0.622, valued at
$21.8k
|
|
| 01/04/2023 |
4
| Dubin Michael F (Director) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 20,000 options to buy
@ $0.622, valued at
$12.4k
|
|
| 01/04/2023 |
4
| Singh Vanila (Director) has filed a Form 4 on Virpax Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options to buy
@ $0.622, valued at
$9.3k
|
|
| 12/29/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/22/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
|